Daclatasvir Plasma Concentration Assessment in HIV–HCV-Coinfected Real-Life Patients

Arends J.E. , Kracht P.A. , Hoepelman A.I. and the European Study Group for Viral Hepatitis (ESGVH). Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clin Microbiol Infect 2016; 22: 846–852.

EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2014; 60: 392–420.

Haute Autorité de Santé. [Management of hepatitis C virus infection with direct-acting antiviral agents]. 2014. French. (Accessed 5 March 2017.) Available from http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-07/hepatite_c_prise_en_charge_anti_viraux_aad.pdf.

Sovaldi^®, Sofosbuvir. RCP EMA. (Accessed 4 January 2017.) Available from http://www.ema.europa.eu/docs/fr_FR/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf.

Daklinza^®, Daclatasvir, RCP EMA. (Accessed 4 January 2017.) Available from http://www.ema.europa.eu/docs/fr_FR/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf.

Bifano M. , Hwang C. , Oosterhuis B. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013; 18: 931–940.

Virlogeux V. , Choupeaux L. , Pradat P. Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: impact of drug concentration on viral load decay. Dig Liver Dis 2016; 48: 1351–1356.

Hill A. , Cooke G. Medicine. Hepatitis C can be cured globally, but at what cost? Science 2014; 345: 141–142.